NCT02723448View on ClinicalTrials.gov

Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

July 23, 2020

Study Completion Date

July 23, 2020

Conditions
Vasculopathy, Retinal, With Cerebral LeukodystrophyCerebroretinal Vasculopathy, Hereditary
Interventions
DRUG

aclarubicin

Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02723448 - Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy | Biotech Hunter | Biotech Hunter